Mutual of America Capital Management LLC Takes Position in Zoetis Inc. (ZTS)
Mutual of America Capital Management LLC purchased a new stake in Zoetis Inc. (NYSE:ZTS) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 67,297 shares of the company’s stock, valued at approximately $4,198,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Wells Fargo & Company MN lifted its holdings in Zoetis by 8.2% in the 2nd quarter. Wells Fargo & Company MN now owns 5,113,948 shares of the company’s stock valued at $319,008,000 after acquiring an additional 389,260 shares during the last quarter. Swiss National Bank lifted its holdings in Zoetis by 8.1% in the 2nd quarter. Swiss National Bank now owns 1,796,380 shares of the company’s stock valued at $112,058,000 after acquiring an additional 133,900 shares during the last quarter. Gladstone Capital Management LLP acquired a new stake in Zoetis in the 2nd quarter valued at about $3,134,000. Victory Capital Management Inc. lifted its holdings in Zoetis by 13.9% in the 2nd quarter. Victory Capital Management Inc. now owns 277,641 shares of the company’s stock valued at $17,320,000 after acquiring an additional 33,894 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Zoetis in the 2nd quarter valued at about $2,233,000. 93.20% of the stock is owned by institutional investors.
ZTS has been the subject of a number of analyst reports. Cantor Fitzgerald set a $75.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research note on Monday, August 14th. Stifel Nicolaus reaffirmed a “buy” rating and set a $65.00 price objective on shares of Zoetis in a research note on Friday, September 1st. Argus reaffirmed a “buy” rating and set a $69.00 price objective (up from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. Deutsche Bank AG reaffirmed a “buy” rating and set a $65.00 price objective (up from $62.00) on shares of Zoetis in a research note on Monday, July 17th. Finally, BidaskClub lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 20th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $65.44.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/09/25/mutual-of-america-capital-management-llc-takes-position-in-zoetis-inc-zts.html.
Zoetis Inc. (NYSE ZTS) opened at 64.16 on Monday. Zoetis Inc. has a one year low of $46.86 and a one year high of $65.83. The stock has a 50 day moving average price of $62.44 and a 200-day moving average price of $59.64. The firm has a market cap of $31.38 billion, a P/E ratio of 36.27 and a beta of 1.02.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter in the previous year, the business posted $0.49 EPS. Zoetis’s revenue for the quarter was up 5.0% on a year-over-year basis. Analysts predict that Zoetis Inc. will post $2.34 EPS for the current fiscal year.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.